Rebecca Griffin, None

N/A
Oncology Biometrics, Late Oncology Statistics, AstraZeneca, United Kingdom

Presentation(s):

• Outcomes by key prognostic factors in EMERALD-1: a Phase 3 study of durvalumab ± bevacizumab with transarterial chemoembolization (TACE) in participants with embolization-eligible unresectable hepatocellular carcinoma (uHCC)

  Tuesday, April 1, 2025
  4:03 PM – 4:12 PM CT